Crossroads Systems 10-Q 10 Mar 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jan. 31, 2017	Mar. 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	CROSSROADS SYSTEMS INC
Entity Central Index Key	1,093,207
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CRDS
Entity Common Stock, Shares Outstanding		1,225,472

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2017	Oct. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,005	$ 2,634
Restricted cash	1,050	1,459
Total cash, cash equivalents and restricted cash	3,055	4,093
Accounts receivable	1,212	1,212
Prepaid expenses and other current assets	244	179
Total current assets	4,511	5,484
Other assets	107	120
Total assets	4,618	5,604
Current liabilities:
Accounts payable	391	339
Accrued expenses	501	637
Deferred revenue	1,068	1,531
Total current liabilities	1,960	2,507
Commitments and contingencies (See Note 4)
Total liabilities	1,960	2,507
Stockholders’ equity:
Convertible preferred stock, $0.001 par value, 25,000,000 shares authorized, 2,591,257 and 2,591,257 shares issued and outstanding, respectively	3	3
Common stock, $0.001 par value, 75,000,000 shares authorized, 1,225,472 and 1,225,472 shares issued and outstanding, respectively	1	1
Additional paid-in capital	239,906	239,835
Accumulated deficit	(237,252)	(236,742)
Total stockholders’ equity	2,658	3,097
Total liabilities and stockholders’ equity	$ 4,618	$ 5,604

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jan. 31, 2017	Oct. 31, 2016
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred Stock, Shares Authorized	25,000,000	25,000,000
Convertible Preferred Stock, Shares Issued	2,591,257	2,591,257
Convertible Preferred Stock, Shares Outstanding	2,591,257	2,591,257
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	75,000,000	75,000,000
Common Stock, Shares Issued	1,225,472	1,225,472
Common Stock, Shares Outstanding	1,225,472	1,225,472

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Revenue:
IP license, royalty and other revenue	$ 19	$ 210
Cost of revenue:
IP license, royalty and other cost of revenue	3	51
Gross profit	16	159
Operating expenses:
General and administrative	863	2,349
Total operating expenses	863	2,349
Loss from operations	(847)	(2,190)
Other expense:
Other income	471	2,671
Income (Loss) from continuing operations	(376)	481
Loss from discontinued operations	0	(618)
Discontinued operations:
Net loss	(376)	(137)
Dividends attributable to preferred stock	(68)	(51)
Net loss available to common stockholders, basic and diluted	$ (444)	$ (188)
Earnings (loss) per share, basic and diluted:
Discontinued operations	$ 0	$ (0.51)
Continuing operations	(0.36)	0.4
Available to common stockholder	$ (0.36)	$ (0.15)
Weighted average number of common shares outstanding, basic and diluted	1,225,472	1,214,634

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Cash flows from operating activities:
Net loss	$ (376)	$ (137)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation from discontinued operations	0	52
Stock-based compensation	71	309
Provision for doubtful accounts receivable	0	(1)
Changes in assets and liabilities:
Accounts receivable	0	(490)
Inventory	0	33
Prepaid expenses and other assets	(51)	(135)
Accounts payable	52	(558)
Accrued expenses	(134)	(675)
Deferred revenue	(464)	(2,518)
Net cash used in operating activities	(902)	(4,120)
Cash flows from investing activities:
Purchase of property and equipment from discontinued operations	0	(10)
Net cash used in investing activities	0	(10)
Cash flows from financing activities:
Preferred dividends	(136)	0
Net cash used in financing activities	(136)	0
Effect of foreign exchange rate on cash and cash equivalents	0	(4)
Change in cash and cash equivalents	(1,038)	(4,134)
Cash, cash equivalents, and restricted cash beginning of period	4,093	11,792
Cash, cash equivalents, and restricted cash end of period	3,055	7,658
Supplemental disclosure of cash flow information:
Cash paid for interest	0	128
Cash paid for income taxes	2	0
Supplemental disclosure of non cash financing activities:
Conversion of preferred stock to common stock	0	302
Common stock dividends issued to preferred shareholders	$ 0	$ 139

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
	Jan. 31, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Basis of Accounting [Text Block]	1. ORGANIZATION AND BASIS OF PRESENTATION The accompanying consolidated financial statements include the accounts of Crossroads Systems, Inc. and its wholly-owned subsidiaries (“Crossroads” or the “Company”). Headquartered in Austin, Texas, Crossroads, a Delaware corporation, is an intellectual property licensing company. Founded in 1996 as a product solutions company, Crossroads created some of the storage industry’s most fundamental patents and has licensed patents to more than 50 companies since 2000. On March 22, 2016, the Company announced the sale of its product business and all related assets to Canadian-based StrongBox Data Solutions, Inc. (“SDSI”) for gross proceeds of $ 1.9 Principles of Consolidation and Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has accumulated significant losses as it developed its past products. Our operations are funded by cash and cash equivalents, as well as from revenue provided by IP licensing, royalties and other revenue. We may also generate revenue from other sources as described in Liquidity and Capital Resources, including without limitation, through obtaining a favorable judgment or settlement in our ongoing litigation concerning infringement of our intellectual property, successfully monetizing all or a portion of the non-‘972 patents, or pursuing other strategic opportunities to generate revenue. If we are not able to obtain additional sources of revenue through these or alternative means, the Company may not have sufficient funds to continue to operate the business. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern for a reasonable period of time. The investment in KIP CR P1 LP (which we refer to as the “partnership” (see Note 6)), of which the Company is a limited partner and of which an affiliate of Fortress Investment Group (“Fortress”) is the general partner, is accounted for using the equity method. The current investment balance is nominal at January 31, 2017. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements. Reclassification Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassification includes assets, liabilities, and certain expenses in sales and marketing, research and development, and general and administrative related to discontinued operations. The amounts for the prior periods have been reclassified to be consistent with the current period presentation and have no impact on previously reported financials. Cash and Cash Equivalents, Restricted Cash Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of 90 days or less at date of purchase. While the Company’s cash and cash equivalents are on deposit with high quality FDIC and Association of German Banks insured financial institutions, at times such deposits exceed insured limits. As of January 31, 2017, total uninsured deposits were $ 2.8 Restricted cash amounted to $ 1.1 IP Revenue Stream Sale On October 30, 2015, the Company entered into an agreement with TQ Zeta LLC, an affiliate of Techquity, and Intrepidus Holdings LLC (collectively, “Techquity”), pursuant to which Techquity will share in the revenue generated from the ‘972 patent litigation. For consideration of $ 10.0 52 20 40 20 100 12 100 0.5 2.7 1.1 Computation of Net Loss Per Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by giving effect to all dilutive potential common shares that were outstanding during the period. Basic earnings per share excludes the dilutive effect of common stock equivalents such as stock options and warrants, while earnings per share, assuming dilution, includes such dilutive effects. Future weighted-average shares outstanding calculations will be impacted by the following factors, among others: (i) the ongoing issuance of common stock associated with stock option and warrant exercises; (ii) any fluctuations in the Company’s stock price, which could cause changes in the number of common stock equivalents included in the earnings per share, assuming dilution computation; and (iii) the issuance of common stock to effect business combinations should the Company enter into such transactions. The Company has excluded all outstanding common stock equivalents from the calculation of diluted net loss per share because all such common stock equivalents are antidilutive for all periods presented. The total number of common stock equivalents excluded from the diluted net loss per common share calculation was 3,153,108 3,164,867 368,765 2,591,257 193,086 Net loss available to common stockholders is calculated by deducting from net loss, preferred dividends paid and accrued of $ 68,000 51,000 Recently Issued Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15 requiring management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern, which is currently performed by the external auditors. Management will be required to perform this assessment for both interim and annual reporting periods and must make certain disclosures if it concludes that substantial doubt exists. This ASU is effective for annual periods, and interim periods within those annual periods, beginning on or after December 15, 2016. The adoption of this guidance is not expected to have a material effect on our financial statements. In March 2016, the FASB issued ASU 2016-09 amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. Additionally, the guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. This ASU is effective for annual periods, and interim periods after those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	3 Months Ended
	Jan. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	2. FAIR VALUE MEASUREMENT Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measurements, a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies, is applied as follows: Level 1 – Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2 – Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 – Valuations based on unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. As of January 31, 2017, the fair value of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximates book value due to the short maturity of these instruments. As of January 31, 2017 and October 31, 2016, the Company held no items which are reported at fair value.

ACCRUED EXPENSES AND DEFERRED R

ACCRUED EXPENSES AND DEFERRED REVENUE	3 Months Ended
	Jan. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	3. ACCRUED EXPENSES AND DEFERRED REVENUE January 31, October 31, 2017 2016 Professional services $ 401 $ 398 Payroll related 86 218 Other 14 21 $ 501 $ 637 January 31, October 31, 2017 2016 License $ 57 $ 72 Deferred revenue stream sale 1,011 1,459 $ 1,068 $ 1,531 Deferred revenue stream sale consists of the remaining amount of consideration received from the sale of a portion of the Company’s IP revenue stream. The deferred revenue will be recognized upon the expenditure of approved legal costs related to the ongoing IP litigation described in Note 4.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jan. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	4. COMMITMENTS AND CONTINGENCIES Leases In accordance with the terms of the March 22, 2016 sale of the Company’s product division, the Company’s office space and equipment lease obligations have been assigned to the purchaser. Legal Proceedings Intellectual Property Litigation The Company has a number of ongoing lawsuits and related proceedings as described below. In discussing these patent litigation proceedings, the following terms will be used: A “Markman hearing” in a patent infringement case is a pre-trial hearing in U.S. District Court, in which the Court hears arguments regarding the meanings of key words used in a disputed patent claim. The outcome of a Markman hearing can play a significant role in whether findings of infringement and validity are made by the Court or by the jury at trial. Depending on the Court, a ruling could be received quickly or could take months after the Markman hearing. An “ Inter Partes inter partes Inter partes An “ Ex Parte Crossroads v. Dot Hill The Company filed a lawsuit on September 11, 2013 against Dot Hill Systems Corp. (“Dot Hill”) styled Crossroads Systems, Inc. v. Dot Hill Systems Corp., Civil Action No. 1:13-CV-800-SS alleging patent infringement of U.S. Patent No. 6,425,035 (the “’035 patent”) and breach of the Amended Settlement and License Agreement dated June 27, 2006 between Crossroads and Dot Hill. The action is pending. The Markman hearing was conducted October 6-7, 2014. Dot Hill moved to join two existing IPR proceedings previously filed against Crossroads by other defendants (one filed by NetApp/Oracle/Huawei and one filed by Cisco/Quantum, each as defined below) and to stay the pending litigation based on those IPR proceedings. On June 16, 2015, Judge Sparks entered the Markman order (the “Markman Order”) construing the claims in a manner favorable to Crossroads and issued an order staying the case pending resolution of the IPR proceedings. The U.S. Patent Office issued rulings in both of the IPR proceedings that Dot Hill had joined, ruling in one that the ‘035 Patent is not unpatentable in view of the prior art raised and in the other that the ‘035 Patent is unpatentable in view of different prior art. Crossroads believes the ruling of unpatentability was in error and has filed an appeal of that ruling with the Federal Circuit Court of Appeals. That appeal is on-going. If the patent asserted against Dot Hill is found partially or entirely invalid at the conclusion of the IPR proceedings, including appeal, Crossroads might be adversely impacted in the litigation proceeding against Dot Hill, including potentially losing the ability to continue with its claims of infringement. In May 2016, Crossroads filed a motion to lift the stay for limited purposes regarding Dot Hill’s failure to pay certain royalties and in July 2016 the Court denied the motion and the stay and this action remains in place. The Company has recorded approximately $ 1.3 134,000 34,000 182,000 38,000 Revenue for the three months ended January 31, 2016 and the accounts receivable balance at January 31, 2017 and October 31, 2016 are concentrated with Dot Hill. In 2015, Seagate Technologies (“Seagate”) purchased Dot Hill. The loss or bankruptcy of Seagate could adversely affect operating results. The Company has not experienced material credit losses in any of the periods presented. The level of sales to any customer may vary from quarter to quarter. However, the Company expects that significant customer concentrations will continue for the foreseeable future. Crossroads v. Oracle, Huawei, Cisco, NetApp, and Quantum These related cases were filed on October 7, 2013, November 26, 2013, and February 18, 2014 in the United States District Court for the Western District of Texas alleging infringement by these parties of one or more patents in the ‘972 patent family. The asserted patents (6,425,035, 7,934,041, 7,987,311 (the “‘311 Patent”) and 7,051,147) were subject to a re-examination of the patents conducted in 2005-2006 by the U.S. Patent Office or were issued after the re-examination. On May 7, 2014, these cases and the Dot Hill case were consolidated for purposes of discovery and a Markman hearing occurred on October 6 and 7, 2014. On June 16, 2015, Judge Sparks entered the Markman Order construing the claims in a manner favorable to Crossroads and entered an order staying these actions in light of the IPR proceedings. During the time Crossroads was pursuing the potential infringers of the ‘972 patent family, the Company gave companies with potentially infringing products the opportunity to license the Company’s proprietary technology. For example, NetApp was first given notice of potential infringement in 2004. Cisco was first given notice of potential infringement in 2002. Quantum has been on notice of its potential infringement since 2006. Oracle acquired several companies that were given notice of potential infringement at least as early as 2009 and Oracle itself has been on notice since then. Despite repeated attempts by Crossroads throughout the years to negotiate licenses to the ‘972 patent family, these companies refused and left Crossroads with no alternatives but litigation. Crossroads believes these companies (and companies they have acquired) have been illegally using Crossroads’ proprietary technology and that the potential compensatory damages could be in excess of $ 200 In response to the lawsuits brought by Crossroads, collectively these defendants filed nineteen inter partes The Company filed a lawsuit on October 7, 2013 against Oracle Corporation (“Oracle”) alleging infringement of U.S. Patent Nos. 6,425,035, 7,051,147 and 7,934,041 (the case is styled Crossroads Systems, Inc. v. Oracle Corporation; Civil Action No. 1:13-cv-0895-SS (W.D. Tex., Austin Division)). The action is pending. The Markman hearing was conducted October 6-7, 2014 and on June 16, 2015, Judge Sparks entered the Markman Order construing the claims in a manner favorable to Crossroads. Oracle filed nine petitions for IPR at the U.S. Patent Office challenging the validity of each of the patents Crossroads asserted in the lawsuit against Oracle. The U.S. Patent Office granted six of those petitions. Based on the IPRs, Oracle filed a motion to stay the litigation pending the outcome of the IPR proceedings, which was granted by the Court. The U.S. Patent Office issued rulings in the IPR proceedings involving Oracle, ruling in one that the ‘035 Patent is not unpatentable over the prior art and ruling in the other five that the ‘035 Patent and ‘147 Patent are unpatentable in view of different prior art. Crossroads believes the rulings of unpatentability were in error and has appealed these rulings to the Federal Circuit Court of Appeals. Those appeals are on-going. If the patents are found partially or entirely invalid during the IPR proceedings, including appeal, Crossroads might be adversely impacted in the litigation proceeding against Oracle, including potentially losing the ability to continue with its claims of infringement. The Company filed a lawsuit on February 18, 2014 against Cisco Systems, Inc. (“Cisco”) alleging infringement of U.S. Patent Nos. 6,425,035 and 7,934,041 (the case is styled Crossroads Systems, Inc. v. Cisco Systems, Inc.; Civil Action No. 1:14-cv-00148-SS (W.D. Tex., Austin Division)). The action is pending. The Markman hearing was conducted October 6-7, 2014 and on June 16, 2015, Judge Sparks entered the Markman Order construing the claims in a manner favorable to Crossroads. Cisco is a party to three petitions for IPR filed at the U.S. Patent Office challenging the validity of each of the patents Crossroads asserted in the lawsuit against Cisco. The U.S. Patent Office granted those petitions. Based on the IPRs, Cisco filed a motion to stay the litigation pending the outcome of the IPR proceedings, which was granted by the Court. The U.S. Patent Office issued rulings in the IPR proceedings involving Cisco, ruling that the ‘035 Patent and ‘147 Patents are unpatentable in view of the cited prior art. Crossroads believes the rulings of unpatentability were in error and has appealed these rulings to the Federal Circuit Court of Appeals. Those appeals are on-going. If the patents are found partially or entirely invalid during the IPR proceedings, including appeal, Crossroads might be adversely impacted in the litigation proceeding against Cisco, including potentially losing the ability to continue with its claims of infringement. The Company filed a lawsuit on February 18, 2014 against NetApp, Inc. (“NetApp”) alleging infringement of U.S. Patent Nos. 6,425,035, 7,934,041, 7,987,311 and 7,051,147 (the case is styled Crossroads Systems, Inc. v. Net App, Inc.; Civil Action No. 1:14-cv-00149-SS (W.D. Tex., Austin Division)). The action is pending. The Markman hearing was conducted October 6-7, 2014 and on June 16, 2015, Judge Sparks entered the Markman Order construing the claims in a manner favorable to Crossroads. NetApp filed seven petitions for IPR filed at the U.S. Patent Office challenging the validity of each of the patents Crossroads asserted in the lawsuit against NetApp. The U.S. Patent Office granted three of those petitions. Based on the IPRs, NetApp filed a motion to stay the litigation pending the outcome of the IPR proceedings, which was granted by the Court. The U.S. Patent Office issued rulings in the IPR proceedings involving NetApp, ruling in one that the ‘035 Patent is not unpatentable over the prior art and ruling in the others that the ‘147 Patent is unpatentable in view of different prior art. Crossroads believes the rulings of unpatentability were in error and has appealed these rulings to the Federal Circuit Court of Appeals. Those appeals are on-going. If the patents are found partially or entirely invalid during the IPR proceedings, including appeal, Crossroads might be adversely impacted in the litigation proceeding against NetApp, including potentially losing the ability to continue with its claims of infringement. On March 4, 2016, after its IPR on the ‘311 Patent was denied, NetApp filed a Reexamination request with the U.S. Patent and Trademark Office challenging the validity of the ‘311 Patent based on a subset of the prior art used in the IPR proceeding. The U.S. Patent and Trademark Office granted the request for Reexamination and issued an office action rejecting the claims of the ‘311 Patent. Crossroads believes this rejection of the claims of the ‘311 Patent to be in error just as we believe the rulings on the IPRs are in error. On September 3, 2016, the Company conducted an interview with the patent examiners to explain why we believe the ‘311 Patent to be valid over the cited prior art. This proceeding is ongoing and could be concluded in 2017. If the ‘311 Patent is found partially or entirely invalid during the Reexamination proceeding, the Company may be adversely impacted in the litigation proceeding against NetApp, including potentially losing the ability to continue with our claims of infringement. The Company filed a lawsuit on February 18, 2014 against Quantum Corporation (“Quantum”) alleging infringement of U.S. Patent Nos. 6,425,035 and 7,934,041 (the case is styled Crossroads Systems, Inc. v. Quantum Corporation; Civil Action No. 1:14-cv-00150-SS (W.D. Tex., Austin Division)). The action is pending. The Markman hearing was conducted October 6-7, 2014 and on June 16, 2015, Judge Sparks entered the Markman Order construing the claims in a manner favorable to Crossroads. Quantum filed three petitions for IPR filed at the U.S. Patent Office challenging the validity of each of the patents Crossroads asserted in the lawsuit against Quantum. The U.S. Patent Office granted those petitions. Based on the IPRs, Quantum filed a motion to stay the litigation pending the outcome of the IPR proceedings, which was granted by the Court. The U.S. Patent Office issued rulings in the three IPR proceedings involving Quantum, ruling that the ‘035 Patent and ‘147 Patents are unpatentable in view of the cited prior art. Crossroads believes the rulings of unpatentability were in error and has appealed those rulings to the Federal Circuit Court of Appeals. Those appeals are on-going. If the patents are found partially or entirely invalid during the IPR proceedings, including appeal, Crossroads might be adversely impacted in the litigation proceeding against Quantum, including potentially losing the ability to continue with its claims of infringement.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	3 Months Ended
	Jan. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	On March 22, 2016 Under the Purchase Agreement, the Company sold and transferred all of the assets related to the Company’s product and support services division (the “Business”), including the Company’s StrongBox and SPHiNX storage solutions, to SDSI. SDSI also assumed certain liabilities of the Company related to the Business, and absorbed the majority of Crossroads’ employees. As consideration under the Purchase Agreement, SDSI paid the Company net proceeds equal to $ 1.9 1.0 5.0 Cash Received $ 1,852 Cash paid to Series F Convertible Preferred shareholders (1,000) Net cash received 852 Fixed Assets (499) Inventory (386) Other Comprehensive Income (110) Expenses incurred (79) Deferred Revenue 1,795 Other Assets and Liabilities 198 Net gain on sale of discontinued operations $ 1,771 Three Months Ended January 31, 2017 2016 (unaudited) (unaudited) Revenue: Product $ - $ 859 IP License, royalty and other - 987 Total revenue - 1,846 Cost of revenue: Product - 309 IP License, royalty and other - 233 Total cost of revenue - 542 Gross profit - 1,304 Operating expenses: Sales and marketing - 826 Research and development - 1,096 Total operating expenses - 1,922 Loss from discontinued operations $ - $ (618)

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Jan. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6. STOCKHOLDERS’ EQUITY On May 25, 2016, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split (the “Reverse Split”) of the outstanding shares of the Company’s common stock at a ratio of one-for-twenty at the Company’s annual meeting of stockholders. The Reverse Split was effective on June 20, 2016. Upon the effectiveness of the Reverse Split, every twenty (20) shares of the Company’s issued and outstanding common stock were automatically combined and reclassified into one (1) share of the Company’s common stock. 2013 Private Placement On March 22, 2013, the Company entered into a securities purchase agreement with certain accredited investors for the issuance and sale in a private placement of 4,231,154 2.0625 8.6 7.9 0.001 2.00 114,138 40.00 0.2019 121,979 6,346 138,000 133,000 135,000 23,000 The Series F Preferred Stock has the rights, qualifications, limitations and restrictions set forth in the Certificate of Designation (the “Certificate of Designation”) filed with the Secretary of State of the State of Delaware on March 28, 2013. The Certificate of Designation authorizes issuance of up to 4,500,000 3,750,000 750,000 9.99 4.99 The Certificate of Designation contains customary anti-dilution protection for proportional adjustments (e.g. stock splits). Upon approval of the full ratchet anti-dilution provisions on June 21, 2013, the warrants were reclassified as a derivative liability and recorded at fair value. This created a scenario for which the shares of Series F Preferred Stock were potentially convertible into more shares of common stock than authorized. Therefore, the Series F Preferred Stock was classified in temporary equity. Upon the expiration of the full ratchet anti-dilution provisions, the Company reclassified the Series F Preferred Stock and warrants to permanent stockholders’ equity following the stockholders vote. During the three months ended January 31, 2017, no shares of Series F Preferred Stock were converted to common shares. Dividends on the Series F Preferred Stock accrue at an annual rate of 5.0 2013 Fortress Credit Agreement On July 22, 2013, the Company issued warrants to purchase 72,727 41.25 0.2019 41.25 2 87,410 The Fortress warrants will expire on the seventh anniversary of the effective date of the Fortress transactions. 2014 Private Placement On March 31, 2014, the Company sold 99,331 45.13 4.5 49,666 49.00 0.2 0.2019 49.00 59,693 2015 Common Stock Offering On January 27, 2015, the Company sold 153,587 46.00 7.1 82,938 55.20 1.1 0.2019 55.20 99,683 2015 Common Stock Rights Offering On July 28, 2015, the Company closed a subscription rights offering for the Company’s common stock (the “Rights Offering”). Under the terms of the Rights Offering, the Company distributed to its common and preferred stockholders one subscription right for each share of the Company’s common or preferred stock owned as of the record date, which entitled the holder to purchase 0.50 25.00 The Company accepted subscriptions for 196,694 4.9 0.4 The Company has the following common stock warrants outstanding at January 31, 2017: Weighted Average Warrants Exercise Warrant Transaction Outstanding Price 2013 Private Placement 121,979 $ 40.00 2013 Fortress Credit Agreement 87,410 $ 41.20 2014 Private Placement 59,693 $ 49.00 2015 Common Stock Offering 99,683 $ 55.20 Total Warrants 368,765

STOCK OPTIONS AND STOCK BASED C

STOCK OPTIONS AND STOCK BASED COMPENSATION	3 Months Ended
	Jan. 31, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. STOCK OPTIONS AND STOCK BASED COMPENSATION The Company has a stock-based compensation plan available to grant incentive stock options, non-qualified stock options and restricted stock to employees and non-employee members of the Board of Directors and advisors. The Company’s 2010 Stock Incentive Plan (the “2010 Plan”), succeeded the 1999 Stock Option/Stock Issuance Plan (the “1999 Plan”). As of January 31, 2017, options to purchase 5,623 The 2010 Plan was approved by the Board of Directors on May 26, 2010 and became effective on August 13, 2010, upon approval by stockholders, and was subsequently amended by the Board of Directors on March 12, 2015 and approved by stockholders on April 24, 2015. A maximum of 683,064 308,826 187,462 As of January 31, 2017, options to purchase an aggregate of 193,086 152,311 436,962 26,344 26,457 January 31, 2017 2016 General and administrative $ 71 $ 193 Discontinued operations - 116 Total stock-based compensation $ 71 $ 309 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Expected volatility is based on historical volatility of the Company’s common stock. The expected term represents an estimate of the time options are expected to remain outstanding based upon historical analysis. The risk-free rate for periods within the contractual life of the option is based on the U.S. treasury yield curve in effect at the time of grant. No variables were used in the Black-Scholes calculation during the quarter ended January 31, 2017 or 2016, as no options were granted during the respective periods. Weighted Average Weighted Remaining Aggregate Number of Average Contractual Term Intrinsic Shares Exercise Price (years) Value ($M) Outstanding and expected to vest at October 31, 2016 198,700 $ 30.16 5.02 $ - Granted - $ - Forfeited (5,614) $ 74.48 Exercised - $ - Outstanding and expected to vest at January 31, 2017 193,086 $ 28.87 4.91 $ - Exercisable at January 31, 2017 152,311 $ 33.33 3.96 $ - The weighted average fair value per option granted during the three months ended January 31, 2017 was $ 0 0 0 At January 31, 2017, there was approximately $ 0.1 0.7 4,625 4,632 $ 0.1 0.2 Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Shares Remaining Average Average Exercise Prices Outstanding Contractual Term Exercise Price Shares Exercise Price $ - $ 5.90 32,000 9.35 $ 5.90 - $ - $ 11.98 $ 21.96 19,819 4.36 $ 18.80 19,819 $ 18.80 $ 24.63 $ 24.63 187 1.75 $ 24.63 187 $ 24.63 $ 25.62 $ 25.62 27,045 6.81 $ 25.62 27,045 $ 25.62 $ 25.96 $ 26.80 24,735 2.65 $ 26.38 20,201 $ 26.28 $ 28.20 $ 33.94 4,441 3.52 $ 29.22 4,283 $ 29.26 $ 34.94 $ 34.94 42,972 0.63 $ 34.94 42,972 $ 34.94 $ 35.27 $ 42.60 22,133 7.00 $ 41.16 21,505 $ 41.18 $ 45.59 $ 91.85 19,344 5.84 $ 55.73 15,889 $ 57.91 $ 98.50 $ 119.80 410 4.94 $ 104.49 410 $ 104.49 $ 5.90 $ 119.80 193,086 4.91 $ 28.87 152,311 $ 33.33

EMPLOYEE BENEFITS

EMPLOYEE BENEFITS	3 Months Ended
	Jan. 31, 2017
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	8. EMPLOYEE BENEFITS The Company established the Crossroads Systems, Inc. 401(k) Savings Plan (the “Savings Plan”), which is a qualified plan under section 401(k) of the Internal Revenue Code. All employees who have attained 18 years of age are eligible to enroll in the Savings Plan. Under the Savings Plan, participating United States employees may defer up to 100% of their pretax salary, but not more than statutory limits. Our matching contributions vest immediately to employees up to four percent of their pretax salary. The Company made matching contributions of $ 9,000 46,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jan. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. RELATED PARTY TRANSACTIONS Discontinued operations consideration paid During the year ended October 31, 2016, the Company’s Board of Directors approved a payment to the Series F Preferred stockholders of the greater of 50 1.0 70 1.0

PREFERRED STOCK RIGHTS

PREFERRED STOCK RIGHTS	3 Months Ended
	Jan. 31, 2017
Preferred Stock Rights [Abstract]
Preferred Stock Rights Disclosure [Text Block]	10. PREFERRED STOCK RIGHTS On May 23, 2014, the Company’s Board of Directors adopted a tax benefit preservation plan (the “Plan”). The Plan is intended to diminish the risk that the Company’s ability to use net operating loss carryforwards to reduce future federal income tax obligations may become substantially limited due to an “ownership change,” as defined in Section 382 of the Internal Revenue Code. The Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of common stock, par value $ 0.001 0.001 to purchase from the Company one one-thousandth of a share of Series G Participating Preferred Stock, 14.00 The rights will become exercisable following (i) the 10th business day (or such later date as may be determined by the Board of Directors) after the public announcement that an acquiring person has acquired beneficial ownership of 4.99 In addition, upon the occurrence of certain events, the exercise price of the rights would be adjusted and holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase common stock at approximately half of market value. Given the potential adjustment of the exercise price of the rights, the rights could cause substantial dilution to a person or group that acquires 4.99% or more of the Company’s common stock on terms not approved by the Company’s Board of Directors. No rights were exercisable at January 31, 2017. There is no impact to the Company's financial results as a result of the adoption of the Plan for the three months ended January 31, 2017 or 2016.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jan. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	11. SUBSEQUENT EVENTS On January 23, 2017, the United States Court of Appeals for the Federal Circuit notified the Company that the oral argument date for the Company’s appeals has been set for Tuesday, March 7, 2017. The appeals before the Federal Circuit relate to the Final Written Decisions issued by the Patent Trial and Appeal Board of the U.S. Patent Office regarding IPR proceedings 2014-01207, 2014-01209, 2014-01226, 2014-01463, 2014-01544, and the IPRs joined to certain of those proceedings (IPRs 2015-00825, 2015-00854, and 2015-00852).

ORGANIZATION AND BASIS OF PRE17

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	3 Months Ended
	Jan. 31, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation and Presentation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has accumulated significant losses as it developed its past products. Our operations are funded by cash and cash equivalents, as well as from revenue provided by IP licensing, royalties and other revenue. We may also generate revenue from other sources as described in Liquidity and Capital Resources, including without limitation, through obtaining a favorable judgment or settlement in our ongoing litigation concerning infringement of our intellectual property, successfully monetizing all or a portion of the non-‘972 patents, or pursuing other strategic opportunities to generate revenue. If we are not able to obtain additional sources of revenue through these or alternative means, the Company may not have sufficient funds to continue to operate the business. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern for a reasonable period of time. The investment in KIP CR P1 LP (which we refer to as the “partnership” (see Note 6)), of which the Company is a limited partner and of which an affiliate of Fortress Investment Group (“Fortress”) is the general partner, is accounted for using the equity method. The current investment balance is nominal at January 31, 2017.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.
Reclassification, Policy [Policy Text Block]	Reclassification Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassification includes assets, liabilities, and certain expenses in sales and marketing, research and development, and general and administrative related to discontinued operations. The amounts for the prior periods have been reclassified to be consistent with the current period presentation and have no impact on previously reported financials.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents, Restricted Cash Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of 90 days or less at date of purchase. While the Company’s cash and cash equivalents are on deposit with high quality FDIC and Association of German Banks insured financial institutions, at times such deposits exceed insured limits. As of January 31, 2017, total uninsured deposits were $ 2.8 Restricted cash amounted to $ 1.1
Revenue Stream Sale [Policy Text Block]	IP Revenue Stream Sale On October 30, 2015, the Company entered into an agreement with TQ Zeta LLC, an affiliate of Techquity, and Intrepidus Holdings LLC (collectively, “Techquity”), pursuant to which Techquity will share in the revenue generated from the ‘972 patent litigation. For consideration of $ 10.0 52 20 40 20 100 12 100 0.5 2.7 1.1
Earnings Per Share, Policy [Policy Text Block]	Computation of Net Loss Per Share Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by giving effect to all dilutive potential common shares that were outstanding during the period. Basic earnings per share excludes the dilutive effect of common stock equivalents such as stock options and warrants, while earnings per share, assuming dilution, includes such dilutive effects. Future weighted-average shares outstanding calculations will be impacted by the following factors, among others: (i) the ongoing issuance of common stock associated with stock option and warrant exercises; (ii) any fluctuations in the Company’s stock price, which could cause changes in the number of common stock equivalents included in the earnings per share, assuming dilution computation; and (iii) the issuance of common stock to effect business combinations should the Company enter into such transactions. The Company has excluded all outstanding common stock equivalents from the calculation of diluted net loss per share because all such common stock equivalents are antidilutive for all periods presented. The total number of common stock equivalents excluded from the diluted net loss per common share calculation was 3,153,108 3,164,867 368,765 2,591,257 193,086 Net loss available to common stockholders is calculated by deducting from net loss, preferred dividends paid and accrued of $ 68,000 51,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15 requiring management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern, which is currently performed by the external auditors. Management will be required to perform this assessment for both interim and annual reporting periods and must make certain disclosures if it concludes that substantial doubt exists. This ASU is effective for annual periods, and interim periods within those annual periods, beginning on or after December 15, 2016. The adoption of this guidance is not expected to have a material effect on our financial statements. In March 2016, the FASB issued ASU 2016-09 amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. Additionally, the guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. This ASU is effective for annual periods, and interim periods after those annual periods, beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.

ACCRUED EXPENSES AND DEFERRED18

ACCRUED EXPENSES AND DEFERRED REVENUE (Tables)	3 Months Ended
	Jan. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands): January 31, October 31, 2017 2016 Professional services $ 401 $ 398 Payroll related 86 218 Other 14 21 $ 501 $ 637
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	Deferred revenue, consists of the following (in thousands): January 31, October 31, 2017 2016 License $ 57 $ 72 Deferred revenue stream sale 1,011 1,459 $ 1,068 $ 1,531

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	3 Months Ended
	Jan. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule Of Disposal Groups Including Discontinued Operations Assets And Liabilities Transferred For Consideration Received [Table Text Block]	The assets and liabilities transferred for consideration received in the second fiscal quarter of 2016 were (in thousands, at book value): Cash Received $ 1,852 Cash paid to Series F Convertible Preferred shareholders (1,000) Net cash received 852 Fixed Assets (499) Inventory (386) Other Comprehensive Income (110) Expenses incurred (79) Deferred Revenue 1,795 Other Assets and Liabilities 198 Net gain on sale of discontinued operations $ 1,771
Disposal Groups, Including Discontinued Operations [Table Text Block]	The amounts in the statement of operations that are part of the discontinued operations are summarized in the following table (in thousands): Three Months Ended January 31, 2017 2016 (unaudited) (unaudited) Revenue: Product $ - $ 859 IP License, royalty and other - 987 Total revenue - 1,846 Cost of revenue: Product - 309 IP License, royalty and other - 233 Total cost of revenue - 542 Gross profit - 1,304 Operating expenses: Sales and marketing - 826 Research and development - 1,096 Total operating expenses - 1,922 Loss from discontinued operations $ - $ (618)

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Jan. 31, 2017
Stockholders Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The Company has the following common stock warrants outstanding at January 31, 2017: Weighted Average Warrants Exercise Warrant Transaction Outstanding Price 2013 Private Placement 121,979 $ 40.00 2013 Fortress Credit Agreement 87,410 $ 41.20 2014 Private Placement 59,693 $ 49.00 2015 Common Stock Offering 99,683 $ 55.20 Total Warrants 368,765

STOCK OPTIONS AND STOCK BASED21

STOCK OPTIONS AND STOCK BASED COMPENSATION (Tables)	3 Months Ended
	Jan. 31, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The Company realized stock-based compensation expense for all awards issued under the Company’s stock plans in the following line items in the consolidated statements of operations: January 31, 2017 2016 General and administrative $ 71 $ 193 Discontinued operations - 116 Total stock-based compensation $ 71 $ 309
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes information about stock option activity for the three months ended January 31, 2017: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Term Intrinsic Shares Exercise Price (years) Value ($M) Outstanding and expected to vest at October 31, 2016 198,700 $ 30.16 5.02 $ - Granted - $ - Forfeited (5,614) $ 74.48 Exercised - $ - Outstanding and expected to vest at January 31, 2017 193,086 $ 28.87 4.91 $ - Exercisable at January 31, 2017 152,311 $ 33.33 3.96 $ -
Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans To Employees and Non Employees By Exercise Price Range [Table Text Block]	The following table shows information about outstanding stock options at January 31, 2017: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Shares Remaining Average Average Exercise Prices Outstanding Contractual Term Exercise Price Shares Exercise Price $ - $ 5.90 32,000 9.35 $ 5.90 - $ - $ 11.98 $ 21.96 19,819 4.36 $ 18.80 19,819 $ 18.80 $ 24.63 $ 24.63 187 1.75 $ 24.63 187 $ 24.63 $ 25.62 $ 25.62 27,045 6.81 $ 25.62 27,045 $ 25.62 $ 25.96 $ 26.80 24,735 2.65 $ 26.38 20,201 $ 26.28 $ 28.20 $ 33.94 4,441 3.52 $ 29.22 4,283 $ 29.26 $ 34.94 $ 34.94 42,972 0.63 $ 34.94 42,972 $ 34.94 $ 35.27 $ 42.60 22,133 7.00 $ 41.16 21,505 $ 41.18 $ 45.59 $ 91.85 19,344 5.84 $ 55.73 15,889 $ 57.91 $ 98.50 $ 119.80 410 4.94 $ 104.49 410 $ 104.49 $ 5.90 $ 119.80 193,086 4.91 $ 28.87 152,311 $ 33.33

ORGANIZATION AND BASIS OF PRE22

ORGANIZATION AND BASIS OF PRESENTATION (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 22, 2016	Jan. 31, 2017	Jan. 31, 2016	Oct. 31, 2015	Oct. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount		3,153,108	3,164,867
Cash, Uninsured Amount		$ 2,800,000
Restricted Cash and Cash Equivalents		1,050,000			$ 1,459,000
Proceeds from Sale of Intangible Assets				$ 10,000,000
Sale Of Intangible Assets, Percentage Of Patent Licenses Issued In First Issue				52.00%
Sale Of Intangible Assets, Maximum Amount Of Patent Licenses Issued In First Issue				$ 20,000,000
Sale Of Intangible Assets, Percentage Of Patent Licenses Issued In Second Issue				40.00%
Sale Of Intangible Assets, Minimum Amount Of Patent Licenses Issued In Second Issue				$ 20,000,000
Sale Of Intangible Assets, Maximum Amount Of Patent Licenses Issued In Second Issue				$ 100,000,000
Sale Of Intangible Assets, Percentage Of Patent Licenses Issued In Third Issue				12.00%
Sale Of Intangible Assets Maximum Amount Of Patent Licenses Issued In Third Issue				$ 100,000,000
Other Income		500,000	$ 2,700,000
Deferred Revenue		1,100,000
Preferred Stock, Amount of Preferred Dividends in Arrears		$ 68,000	$ 51,000
Proceeds from Sale of Productive Assets	$ 1,900,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount		368,765
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount		2,591,257
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount		193,086

ACCRUED EXPENSES AND DEFERRED23

ACCRUED EXPENSES AND DEFERRED REVENUE (Details) - USD ($) $ in Thousands	Jan. 31, 2017	Oct. 31, 2016
Deferred Revenue Arrangement [Line Items]
Professional services	$ 401	$ 398
Payroll related	86	218
Other	14	21
Accrued Liabilities Current	$ 501	$ 637

ACCRUED EXPENSES AND DEFERRED24

ACCRUED EXPENSES AND DEFERRED REVENUE (Details 1) - USD ($) $ in Thousands	Jan. 31, 2017	Oct. 31, 2016
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 1,068	$ 1,531
License [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	57	72
Deferred revenue stream sale [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 1,011	$ 1,459

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Commitments And Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 200,000,000
Dot Hill [Member]
Commitments And Contingencies [Line Items]
Deferred Revenue, Revenue Recognized	182,000
Cost of Revenue	38,000
Dot Hill [Member] | Cost of Sales [Member]
Commitments And Contingencies [Line Items]
Litigation Settlement, Amount	34,000	$ 34,000
Dot Hill [Member] | Sales Revenue, Net [Member]
Commitments And Contingencies [Line Items]
Litigation Settlement, Amount	134,000	$ 134,000
Dot Hill Systems Corp [Member]
Commitments And Contingencies [Line Items]
Due from Related Parties, Current	$ 1,300,000

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) $ in Thousands	3 Months Ended
	Jan. 31, 2017USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash Received	$ 1,852
Cash paid to Series F Convertible Preferred shareholders	(1,000)
Net cash received	852
Fixed Assets	(499)
Inventory	(386)
Other Comprehensive Income	(110)
Expenses incurred	(79)
Deferred Revenue	1,795
Other Assets and Liabilities	198
Net gain on sale of discontinued operations	$ 1,771

DISCONTINUED OPERATIONS (Deta27

DISCONTINUED OPERATIONS (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Revenue:
IP License, royalty and other	$ 19	$ 210
Cost of revenue:
IP License, royalty and other	3	51
Gross profit	16	159
Operating expenses:
Total operating expenses	863	2,349
Loss from discontinued operations	0	(618)
Discontinued Operations [Member]
Revenue:
Product	0	859
IP License, royalty and other	0	987
Total revenue	0	1,846
Cost of revenue:
Product	0	309
IP License, royalty and other	0	233
Total cost of revenue	0	542
Gross profit	0	1,304
Operating expenses:
Sales and marketing	0	826
Research and development	0	1,096
Total operating expenses	0	1,922
Loss from discontinued operations	$ 0	$ (618)

DISCONTINUED OPERATIONS (Deta28

DISCONTINUED OPERATIONS (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase and Assignment Agreement, Inception Date	Mar. 22, 2016
Proceeds from Divestiture of Businesses	$ 1,852
Cash Divested from Deconsolidation	1,000
Purchase and Assignment Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses	1,900
Series F Preferred Stock [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash Divested from Deconsolidation	$ 1,000	$ 1,000
Preferred Stock, Dividend Rate, Percentage	5.00%

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - $ / shares	Jan. 31, 2017	Jan. 27, 2015	Mar. 31, 2014	Jul. 22, 2013
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	368,765
2013 Private Placement Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	121,979
Weighted Average Exercise Price (in dollars per share)	$ 40
2013 Fortress Credit Agreement Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	87,410			72,727
Weighted Average Exercise Price (in dollars per share)	$ 41.2			$ 41.25
2014 Private Placement Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	59,693
Weighted Average Exercise Price (in dollars per share)	$ 49		$ 49
2015 Common Stock Offering [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	99,683
Weighted Average Exercise Price (in dollars per share)	$ 55.2	$ 55.20

STOCKHOLDERS' EQUITY (Details T

STOCKHOLDERS' EQUITY (Details Textual)	1 Months Ended						3 Months Ended	12 Months Ended
	Aug. 31, 2015$ / sharesshares	Jul. 28, 2015USD ($)$ / sharesshares	Jan. 27, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Jul. 22, 2013$ / shares$ / Rateshares	Mar. 22, 2013USD ($)$ / sharesshares	Jan. 31, 2017USD ($)$ / sharesshares	Oct. 31, 2016USD ($)shares
Class of Stock [Line Items]
Payments of Stock Issuance Costs | $		$ 400,000
Preferred Stock, Shares Authorized							25,000,000	25,000,000
Class of Warrant or Right, Outstanding							368,765
Common Stock, Shares Subscribed but Unissued		196,694
Common Stock, Value, Subscriptions | $		$ 4,900,000
Subscription Price Per Share | $ / shares		$ 25
Purchase Of Common Stock Shares		0.50
Stockholders' Equity, Reverse Stock Split							Upon the effectiveness of the Reverse Split, every twenty (20) shares of the Companys issued and outstanding common stock were automatically combined and reclassified into one (1) share of the Companys common stock.
2013 Private Placement Warrant [Member]
Class of Stock [Line Items]
Exercise Price Per Share Of Common Stock Issued By Conversion Of Warrants | $ / shares	$ 0.2019
Securities Purchase Agreement, Exercise Price Of Warrants Issued | $ / shares						$ 40
Warrants Convertible Beneficial Conversion Feature | $								$ 6,346
Stock Issued During Period, Value, Stock Dividend | $								138,000
Class of Warrant or Right, Outstanding							121,979
Accrued Liabilities for Commissions, Expense and Taxes | $							$ 23,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 40
Dividends, Preferred Stock, Cash | $							$ 135,000	$ 133,000
2013 Fortress Credit Agreement Warrant [Member]
Class of Stock [Line Items]
Exercise Price Per Share Of Common Stock Issued By Conversion Of Warrants | $ / shares	0.2019
Securities Purchase Agreement, Price Per Unit Of Units Issuable | $ / Rate					41.25
Class of Warrant or Right, Outstanding					72,727		87,410
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 41.25		$ 41.2
Payment Of Call Option | $							$ 2,000,000
2014 Private Placement Warrant [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues One				99,331
Shares Issued, Price Per Share | $ / shares				$ 45.13
Number Of Common Stock, Shares Granted By Issue Of Warrants Under Private Placement				49,666
Exercise Price Per Share Of Common Stock Issued By Conversion Of Warrants | $ / shares	$ 0.2019			$ 49
Payments of Stock Issuance Costs | $				$ 200,000
Class of Warrant or Right, Outstanding							59,693
Proceeds from Issuance of Private Placement | $				$ 4,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 49			$ 49
2015 Common Stock Offering
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues One			153,587
Shares Issued, Price Per Share | $ / shares			$ 46
Number Of Common Stock, Shares Granted By Issue Of Warrants Under Private Placement	0.2019		82,938
Exercise Price Per Share Of Common Stock Issued By Conversion Of Warrants | $ / shares			$ 55.20
Payments of Stock Issuance Costs | $			$ 1,100,000
Class of Warrant or Right, Outstanding							99,683
Proceeds from Issuance of Private Placement | $			$ 7,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 55.20				$ 55.2
Series F1 Convertible Preferred Stock [Member] | 2013 Private Placement Warrant [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage							9.99%
Series F2 Convertible Preferred Stock [Member] | 2013 Private Placement Warrant [Member]
Class of Stock [Line Items]
Equity Method Investment, Ownership Percentage							4.99%
Series F Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Dividend Rate, Percentage							5.00%
Certificate Of Designation [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized							4,500,000
Preferred Stock, Voting Rights							Such beneficial ownership limitations may be increased or decreased by a holder of Sub-Series F-1 to any percentage not in excess of 19.99% after providing notice of such increase or decrease to the Company. For as long as at least 90% of the aggregate number of shares of Sub-Series F-1 issued on the original issue date are outstanding, the holders of such Sub-Series F-1, voting as a single class, will be entitled to elect two directors of the Company. If less than 90%, but at least 20%, of such shares of Sub-Series F-1 are outstanding, such holders, voting as a single class, will be entitled to elect one director of the Company. As of the date hereof, less than 78% of the aggregate number of shares of Sub-Series F-1 are outstanding, as the remainder have been voluntarily converted into common stock at the option of the holders. Therefore, the holders of the Sub-Series F-1 shares are entitled to elect one director to the Board of Directors. The holders of Sub-Series F-2 will not be entitled to vote on the directors elected by the holders of Sub-Series F-1. The holders of shares of the Series F Preferred Stock are entitled to a liquidation preference equal to the original issuance price plus any unpaid dividends.
Certificate Of Designation [Member] | Series F1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized							3,750,000
Certificate Of Designation [Member] | Series F2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized							750,000
Investors [Member]
Class of Stock [Line Items]
Securities Purchase Agreement, Exercise Price Of Warrants Issued | $ / shares						$ 2.0625
Investors [Member] | 2013 Private Placement Warrant [Member]
Class of Stock [Line Items]
Securities Purchase Agreement, Number Of Units Issuable						4,231,154
Securities Purchase Agreement, Value Of Units Issuable | $						$ 8,600,000
Securities Purchase Agreement, Proceeds From Issuance Of Units | $						$ 7,900,000
Securities Purchase Agreement, Number Of Warrants Issued						114,138
Units Par Or Stated Value Per Share | $ / shares						$ 0.001
Investor One [Member] | 2013 Private Placement Warrant [Member]
Class of Stock [Line Items]
Securities Purchase Agreement, Exercise Price Of Warrants Issued | $ / shares						$ 2

STOCK OPTIONS AND STOCK BASED31

STOCK OPTIONS AND STOCK BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 71	$ 309
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	0	116
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 71	$ 193

STOCK OPTIONS AND STOCK BASED32

STOCK OPTIONS AND STOCK BASED COMPENSATION (Details 1) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and expected to vest at October 31, 2016	198,700
Number of Shares, Granted	0
Number of Shares, Forfeited	(5,614)
Number of Shares, Exercised	0
Number of Shares, Outstanding and expected to vest at January 31, 2017	193,086	198,700
Number of Shares, Exercisable at January 31, 2017	152,311
Weighted Average Exercise Price, Outstanding and expected to vest at October 31, 2016 (in dollars per share)	$ 30.16
Weighted Average Exercise Price, Granted (in dollars per share)	0
Weighted Average Exercise Price, Forfeited (in dollars per share)	74.48
Weighted Average Exercise Price, Exercised (in dollars per share)	0
Weighted Average Exercise Price, Outstanding and expected to vest at January 31, 2017	28.87	$ 30.16
Weighted Average Exercise Price, Exercisable at January 31, 2017 (in dollars per share)	$ 33.33
Weighted Average Remaining Contractual Term, Outstanding and expected to vest at end of the period (in years)	4 years 10 months 28 days	5 years 7 days
Weighted Average Remaining Contractual Term, Exercisable at January 31, 2017 (in years)	3 years 11 months 16 days
Aggregate Intrinsic Value, Outstanding and expected to vest at October 31, 2016	$ 0
Aggregate Intrinsic Value, Outstanding and expected to vest at January 31, 2017	0	$ 0
Aggregate Intrinsic Value, Exercisable at January 31, 2017 (in dollars)	$ 0

STOCK OPTIONS AND STOCK BASED33

STOCK OPTIONS AND STOCK BASED COMPENSATION (Details 2)	3 Months Ended
	Jan. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	$ 5.90
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 119.80
Options Outstanding, Shares Outstanding (in shares) | shares	193,086
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	4 years 10 months 28 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 28.87
Options Exercisable, Shares (in shares) | shares	152,311
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 33.33
Range Of Exercise Prices One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	0
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 5.90
Options Outstanding, Shares Outstanding (in shares) | shares	32,000
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	9 years 4 months 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.90
Options Exercisable, Shares (in shares) | shares	0
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0
Range Of Exercise Prices Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	11.98
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 21.96
Options Outstanding, Shares Outstanding (in shares) | shares	19,819
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	4 years 4 months 10 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 18.80
Options Exercisable, Shares (in shares) | shares	19,819
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 18.80
Range Of Exercise Prices Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	24.63
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 24.63
Options Outstanding, Shares Outstanding (in shares) | shares	187
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	1 year 9 months
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 24.63
Options Exercisable, Shares (in shares) | shares	187
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 24.63
Range Of Exercise Prices Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	25.62
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 25.62
Options Outstanding, Shares Outstanding (in shares) | shares	27,045
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	6 years 9 months 22 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 25.62
Options Exercisable, Shares (in shares) | shares	27,045
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 25.62
Range Of Exercise Prices Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	25.96
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 26.80
Options Outstanding, Shares Outstanding (in shares) | shares	24,735
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	2 years 7 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 26.38
Options Exercisable, Shares (in shares) | shares	20,201
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 26.28
Range Of Exercise Prices Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	28.20
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 33.94
Options Outstanding, Shares Outstanding (in shares) | shares	4,441
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	3 years 6 months 7 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 29.22
Options Exercisable, Shares (in shares) | shares	4,283
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 29.26
Range Of Exercise Prices Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	34.94
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 34.94
Options Outstanding, Shares Outstanding (in shares) | shares	42,972
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	7 months 17 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 34.94
Options Exercisable, Shares (in shares) | shares	42,972
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 34.94
Range Of Exercise Prices Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	35.27
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 42.60
Options Outstanding, Shares Outstanding (in shares) | shares	22,133
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	7 years
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 41.16
Options Exercisable, Shares (in shares) | shares	21,505
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 41.18
Range Of Exercise Prices Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	45.59
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 91.85
Options Outstanding, Shares Outstanding (in shares) | shares	19,344
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	5 years 10 months 2 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 55.73
Options Exercisable, Shares (in shares) | shares	15,889
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 57.91
Range Of Exercise Prices Ten [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit (in dollars per share)	98.50
Range of Exercise Prices, Upper Limit (in dollars per share)	$ 119.80
Options Outstanding, Shares Outstanding (in shares) | shares	410
Options Outstanding, Weighted Average Remaining Contractual Term (in years)	4 years 11 months 8 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 104.49
Options Exercisable, Shares (in shares) | shares	410
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 104.49

STOCK OPTIONS AND STOCK BASED34

STOCK OPTIONS AND STOCK BASED COMPENSATION (Details Textual) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Oct. 31, 2016	May 25, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options To Employees and Non Employees Outstanding Number (in shares)	193,086		198,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$ 0
Proceeds from Stock Options Exercised	$ 0
Expected Weighted Average Period Of Recognition Of Compensation Cost Related To Stock Options To Employees and Non Employees	8 months 12 days
Stock Options Vested By Shares To Employees and Non Employees During Period	4,625	4,632
Stock Options Vested To Value Of Employees and Non Employees During Period	$ 100,000	$ 200,000
Number of Shares, Granted	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0
Stock Option Plan 1999 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options To Employees and Non Employees Outstanding Number (in shares)	5,623
Stock Options Authorized To Be Issued To Employees and Non Employees	193,086
Stock Option Plan 2010 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Vested By Shares To Employees and Non Employees During Period	152,311
Number of Shares, Granted	26,457
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	26,344
Common Stock, Capital Shares Reserved for Future Issuance	436,962
Stock Option Plan 2010 [Member] | Board Of Directors [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options To Employees and Non Employees Outstanding Number (in shares)	187,462
Stock Options Authorized To Be Issued To Employees and Non Employees				683,064
Number of Shares, Granted	308,826

EMPLOYEE BENEFITS (Details Text

EMPLOYEE BENEFITS (Details Textual) - USD ($)	3 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
401(k) Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 9,000	$ 46,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jan. 31, 2017	Oct. 31, 2016
Related Party Transaction [Line Items]
Selling Expense		$ 1,000
Cash Divested from Deconsolidation	$ 1,000
Series F Preferred Stock [Member]
Related Party Transaction [Line Items]
Approval For Sale Of Business, Percentage		70.00%
Percentage Of Net Proceeds for Shareholders		50.00%
Cash Divested from Deconsolidation	$ 1,000	$ 1,000

PREFERRED STOCK RIGHTS (Details

PREFERRED STOCK RIGHTS (Details Textual) - $ / shares	1 Months Ended	3 Months Ended
	May 23, 2014	Jan. 31, 2017	Oct. 31, 2016
Class of Stock [Line Items]
Preferred Stock, Participation Rights		one right for each outstanding share of common stock, par value $0.001 per share, and Series F Preferred Stock, par value $0.001 per share, of the Company to stockholders of record as of the close of business on June 4, 2014.
Preferred Stock, Par Or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Rights Entitlement		to purchase from the Company one one-thousandth of a share of Series G Participating Preferred Stock,
Preferred Stock Rights Exercisable, Beneficial Ownership Percentage of Common Stock	4.99%
Series G Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par Or Stated Value Per Share	$ 0.001
Preferred Stock, Exercise Price Per One One-Thousandth	$ 14